Title | The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. |
Publication Type | Journal Article |
Year of Publication | 2008 |
Authors | Jais J-P, Haioun C, Molina TJ, Rickman DS, De Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, Salles G, Leroy K |
Corporate Authors | Groupe d'Etude des Lymphomes de l'Adulte |
Journal | Leukemia |
Volume | 22 |
Issue | 10 |
Pagination | 1917-24 |
Date Published | 2008 Oct |
ISSN | 1476-5551 |
Keywords | Adaptor Proteins, Signal Transducing, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, APOBEC-3G Deaminase, Cyclophosphamide, Cytidine Deaminase, Cytoskeletal Proteins, DNA-Binding Proteins, Doxorubicin, Female, Forkhead Transcription Factors, Gene Expression Profiling, Humans, LIM Domain Proteins, Lymphoma, Large B-Cell, Diffuse, Male, Metalloproteins, Middle Aged, Multivariate Analysis, Prednisone, Proto-Oncogene Proteins, rab GTP-Binding Proteins, Repressor Proteins, Reverse Transcriptase Polymerase Chain Reaction, Rituximab, Vincristine |
Abstract | Gene expression profiles have been associated with clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-containing chemotherapy. Using Affymetrix HU133A microarrays, we analyzed the lymphoma transcriptional profile of 30 patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and 23 patients treated with rituximab (R)-CHOP in the Groupe d'Etude des Lymphomes de l'Adulte clinical centers. We used this data set to select transcripts showing an association with progression-free survival in all patients or showing a differential effect in the two treatment groups. We performed real-time quantitative reverse transcription-PCR in the 23 R-CHOP samples of the screening set and an additional 44 R-CHOP samples set to evaluate the prognostic significance of these transcripts. In these 67 patients, the level of expression of 16 genes and the cell-of-origin classification were significantly associated with overall survival, independently of the International Prognostic Index. A multivariate model comprising four genes of the cell-of-origin signature (LMO2, MME, LPP and FOXP1) and two genes related to immune response, identified for their differential effects in R-CHOP patients (APOBEC3G and RAB33A), demonstrated a high predictive efficiency in this set of patients, suggesting that both features affect outcome in DLBCL patients receiving immunochemotherapy. |
DOI | 10.1038/leu.2008.188 |
Alternate Journal | Leukemia |
PubMed ID | 18615101 |
Related Faculty:
David Rickman, Ph.D.